What is the official website of Novartis Israel ?

The official website of Novartis Israel is https://www.novartis.com/il-he/.

What is Novartis Israel's cybersecurity risk score?

Novartis Israel has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Israel experienced?

According to Rankiteo, Novartis Israel currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Israel been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Israel has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Israel have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Israel is not certified under SOC 2 Type 1.

Does Novartis Israel have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Israel does not hold a SOC 2 Type 2 certification.

Does Novartis Israel comply with GDPR ?

According to Rankiteo, Novartis Israel is not listed as GDPR compliant.

Does Novartis Israel have PCI DSS certification ?

According to Rankiteo, Novartis Israel does not currently maintain PCI DSS compliance.

Does Novartis Israel comply with HIPAA ?

According to Rankiteo, Novartis Israel is not compliant with HIPAA regulations.

Does Novartis Israel have ISO 27001 certification ?

According to Rankiteo,Novartis Israel is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Israel operate in ?

Novartis Israel operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Israel have ?

Novartis Israel employs approximately 41 people worldwide.

Does Novartis Israel own any subsidiaries ?

Novartis Israel presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Israel have ?

Novartis Israel's official LinkedIn profile has approximately 980 followers.

What is the NAICS classification code for Novartis Israel ?

Novartis Israel is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Israel have a Crunchbase profile ?

No, Novartis Israel does not have a profile on Crunchbase.

Does Novartis Israel have a LinkedIn profile ?

Yes, Novartis Israel maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-israel.

How many cybersecurity incidents has Novartis Israel experienced ?

As of June 21, 2026, Rankiteo reports that Novartis Israel has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Israel have ?

Novartis Israel has an estimated 5,695 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Israel faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Israel

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novartis Israel Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. Around 108,000 people of more than 140 nationalities work at Novartis around the world. See our community guidelines: http://bit.ly/2JnT2CP

Novartis Israel A.I CyberSecurity Scoring

Scoring History

Novartis Israel

Novartis Israel CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Israel

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Israel Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Israel

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Israel in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Israel in 2026.

Incident Types Novartis Israel vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Israel in 2026.

Incident History - Novartis Israel (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Israel Subsidiaries

Novartis Israel

Pharmaceutical Manufacturing

Website: https://www.novartis.com/il-he/

Company Size: 41

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Loading…

Novartis Israel Similar Companies

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Loading…

NEWS

Novartis Israel CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 03, 2025 08:00 AM

JPMorgan's tech team hired an Amazon director and Pfizer executive as MDs

JPMorgan has been hiring multiple senior technologists, but they're not all coming from finance. Two new managing directors (MDs),...

Read Article

May 20, 2025 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

July 19, 2021 07:00 AM

Rapid7 acquires IntSights for close to $400 million

The Israeli cybersecurity company is set to become Rapid7's R&D center in Israel)

Read Article

July 15, 2021 07:00 AM

Rapid7 in advanced talks to acquire Israel's IntSights for $350 million

The Israeli cybersecurity company has raised $70 million to date and counts Forbes, Novartis and Ford among its clients)

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56355

SUMMARY

GNU Savannah Administration Savane through 3.17 uses untrusted data as part of authorization.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-56347

SUMMARY

AVideo TopMenu plugin through version 26.0 contains a stored cross-site scripting vulnerability in menu item rendering due to missing output encoding of icon classes, URLs, and text labels. Attackers can inject malicious JavaScript through unescaped menu item fields that execute for all site visitors, potentially stealing session cookies or performing unauthorized actions.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.1)

cvss3

Base Score: 6.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.7

Exploitability

2.8

REFERENCES

CVE-2026-56346

SUMMARY

AVideo through version 25.0 contains an authentication bypass vulnerability in the decryptMessage.json.php endpoint that allows unauthenticated users to decrypt PGP messages. Remote attackers can submit private keys, ciphertext, and passphrases to perform server-side decryption without credentials, exposing key material to logs and enabling resource exhaustion attacks.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:L

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

3.9

REFERENCES

CVE-2026-56345

SUMMARY

AVideo through 29.0 contains an authorization bypass vulnerability in the Meet plugin's uploadRecordedVideo.json.php endpoint that derives the target users_id from the uploaded filename without verification. An attacker with knowledge of the Meet shared secret can craft a malicious file upload with a filename containing an arbitrary users_id to invoke passwordless User->login() and establish an authenticated session as any user including admin. Attackers can obtain the Meet shared secret through path-traversal vulnerabilities or timing attacks against checkToken.json.php, then POST a crafted file to uploadRecordedVideo.json.php with a filename like '1-anything.mp4' to hijack admin sessions and gain full account takeover.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.2

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.2

REFERENCES

CVE-2026-56342

SUMMARY

AVideo through version 27.0 contains a server-side request forgery vulnerability in plugin/Live/test.php that allows authenticated administrators to read arbitrary URLs via the statsURL parameter, which lacks isSSRFSafeURL() validation and accepts requests to private IP ranges and cloud metadata endpoints. Attackers can exploit this by crafting requests to internal services, cloud metadata endpoints like 169.254.169.254, and localhost to retrieve sensitive information including IAM credentials, internal service responses, and network configuration details.

Published

Date2026-06-20

Updated

Date2026-06-20

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:N/A:N

cvss4

Base Score: 6.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…